eISSN: 1897-4317
ISSN: 1895-5770
Gastroenterology Review/Przegląd Gastroenterologiczny
Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Rada naukowa Bazy indeksacyjne Prenumerata Kontakt Zasady publikacji prac Opłaty publikacyjne
Panel Redakcyjny
Zgłaszanie i recenzowanie prac online
NOWOŚĆ
Portal dla gastroenterologów!
www.egastroenterologia.pl
SCImago Journal & Country Rank
3/2024
vol. 19
 
Poleć ten artykuł:
Udostępnij:
Artykuł oryginalny

The effects of hyperbaric treatment on perianal fistula activity in patients with Crohn’s disease

Grażyna Piotrowicz
1
,
Jacek Kot
2, 3
,
Andrzej Babicki
4
,
Piotr Banaszkiewicz
1
,
Adam Piotrowicz
4
,
Magdalena Rzeszutek
1
,
Agata Rudnik
1, 5
,
Piotr Zientara
6
,
Joanna Adamska-Mieruszewska
6
,
Grażyna Rydzewska
7, 8

  1. Department of Gastroenterology, Self-Dependent Health Care Unit of Ministry of Interior and Administration, Gdansk, Poland
  2. National Centre for Hyperbaric Medicine Institute of Maritime and Tropical Medicine in Gdynia, Medical University of Gdansk, Poland
  3. Department of Hyperbaric Medicine and Sea Rescue, University Centre for Maritime and Tropical Medicine, Gdynia, Poland
  4. Department of Surgery, Self-Dependent Health Care Unit of Ministry of Interior and Administration, Gdansk, Poland
  5. Institute of Psychology, University of Gdansk, Gdansk, Poland
  6. Faculty of Economics, University of Gdansk, Gdansk, Poland
  7. Department of Internal Medicine and Gastroenterology, Central Clinical Hospital of the Ministry of Interior and Administration, Warsaw, Poland
  8. Collegium Medicum, Jan Kochanowski University, Kielce, Poland
Data publikacji online: 2024/09/27
Plik artykułu:
Pobierz cytowanie
 
Metryki PlumX:
 
1. Rossignol DA. Hyperbaric oxygen treatment for inflammatory bowel disease: a systematic review and analysis. Med Gas Res 2012; 2: 6.
2. Rugtveit J, Nilsen EM, Bakka A, et al. Cytokine profiles differ in newly recruited and resident subsets of mucosal macrophages from inflammatory bowel disease. Gastroenterology 1997; 112: 1493-505.
3. Schottlender N, Gottfried I, Ashery U. Hyperbaric oxygen treatment: effects on mitochondrial function and oxidative stress. Biomolecules 2021; 11: 1827.
4. De Wolde SD, Hulskes RH, Weenink RP, et al. The effects of hyperbaric oxygenation on oxidative stress, inflammation and angiogenesis. Biomolecules 2021; 11: 1210.
5. Pagoldh M, Hultgren E, Arnell P, Eriksson A. Hyperbaric oxygen therapy does not improve the effects of standardized treatment in a severe attack of ulcerative colitis: a prospective randomized study. Scand J Gastroenterol 2013; 48: 1033-40.
6. Donoghue DP, Hyland JM. Perianal Crohn’s disease. Eur J Gastroenterol Hepatol 1997; 9: 235-6.
7. Colombel JF, Mathieu D, Bouault JM, et al. Hyperbaric oxygenation in severe perineal Crohn’s disease. Dis Colon Rectum 1995; 38: 609-14.
8. Taxonera C, Schwartz DA, García-Olmo D. Emerging treatments for complex perianal fistula in Crohn’s disease. World J Gastroenterol 2009; 15: 4263-42.
9. Daperno M, D’Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: the SES-CD. Gastrointest Endosc 2004; 60: 505-12.
10. Torres J, Bonovas S, Doherty G, et al. ECCO guideline sumarized. J Crohn’s Colitis 2020; 14: 4-22.
11. Pikarsky AJ, Gervaz P, Wexner SD. Perianal Crohn disease a new scoring system to evaluate and predict outcome of surgical intervention. Arch Surg 2002; 137: 774-8.
12. Sandborn WJ, Feagan BG, Hanauer SB, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn’s disease. Gastroenterology 2002; 122: 512-30.
13. Armuzzi A, Pugliese D. Hyperbaric oxygen therapy: more hope than hype for future treatment of perianal fistulizing Crohn’s disease? United European Gastroenterol J 2022; 10: 143-4.
14. Wang X, Shen B. Advances in perianal disease associated with Crohn’s disease-evolving approaches. Gastrointest Endosc Clin N Am 2019; 29: 515-30.
15. Lansdorp CA, Buskens CJ, Gecse KB, et al. Hyperbaric oxygen therapy for the treatment of perianal fistulas in 20 patients with Crohn’s disease: results of the HOT-TOPIC trial after 1-year follow-up. United European Gastroenterol J 2022; 10: 160-8.
16. McCurdy J, Siw KCK, Kandel R, et al. The effectiveness and safety of hyperbaric oxygen therapy in various phenotypes of inflammatory bowel disease: systematic review with meta-analysis. Inflamm Bowel Dis 2022; 28: 611-21.
17. Singh AK, Jha DK, Jena A, et al. Hyperbaric oxygen therapy in inflammatory bowel disease: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2021; 33 (Suppl 1): e564-73.
18. Kaur H, Kochhar GS, Dulai PS. Role of hyperbaric oxygen therapy in patients with inflammatory bowel disease. Curr Opin Gastroenterol 2023; 39: 263-7.
19. Wu X, Liang TY, Wang Z, Chen G. The role of hyperbaric oxygen therapy in inflammatory bowel disease: a narrative review. Med Gas Res 2021; 11: 66-71.
20. You JH, Jiang JL, He WB, et al. Addition of hyperbaric oxygen therapy versus usual care alone for inflammatory bowel disease: a systematic review and meta-analysis. Heliyon 2022; 8: e11007.
21. Kim PH, Park SH, Jin K, et al. Supplementary anal imaging by magnetic resonance enterography in patients with Crohn’s disease not suspected of having perianal fistulas. Clin Gastroenterol Hepatol 2020; 18: 415-23.
22. Panés J, Rimola J. Perianal fistulizing Crohn’s disease: pathogenesis, diagnosis and therapy. Nat Rev Gastroenterol Hepatol 2017; 14: 652-64.
23. Agrawal G, Borody T, Turner R, et al. Combining infliximab, anti-MAP and hyperbaric oxygen therapy for resistant fistulizing Crohn’s disease. Future Sci OA 2015; 1: FSO77.
24. Aguilera-Castro L, Ferre-Aracil C, Garcia-Garcia-de-Paredes A, et al. Management of complex perianal Crohn’s disease. Ann Gastroenterol 2017; 30: 33-44.
25. McCurdy J, Siw KCK, Kandel R, et al. The effectiveness and safety of hyperbaric oxygen therapy in various phenotypes of inflammatory bowel disease: systematic review with meta-analysis. Inflamm Bowel Dis 2022; 28: 611-21.
26. Gergely M, Prado E, Deepak P. Management of refractory inflammatory bowel disease. Curr Opin Gastroenterol 2022; 38: 347-57.
Copyright: © 2024 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
© 2024 Termedia Sp. z o.o.
Developed by Bentus.